Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant,hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments (CBYL719X2402)

  • Details

ClinicalTrials.gov ID: NCT03056755
Diagnosis Type: NA
USOR Number: 17026

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Endometrial Cancer

Clinical Trial at: Texas Oncology - Dallas

D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

  • Details

ClinicalTrials.gov ID: NCT04269200
Diagnosis Type: NA
USOR Number: 19221

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Dallas

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

  • Details

ClinicalTrials.gov ID: NCT03748641
Diagnosis Type: NA
USOR Number: 18103

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Dallas

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Dallas

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number: 11282

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Dallas

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: NA
USOR Number: 19208

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Essential Thrombocythemia

Clinical Trial at: Texas Oncology - Dallas

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

  • Details

ClinicalTrials.gov ID: NCT03165734
Diagnosis Type: NA
USOR Number: 19171

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Texas Oncology - Dallas

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

  • Details

ClinicalTrials.gov ID: NCT03165734
Diagnosis Type: NA
USOR Number: 19171

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Leukemia

Clinical Trial at: Texas Oncology - Dallas

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

  • Details

ClinicalTrials.gov ID: NCT03734016
Diagnosis Type: NA
USOR Number: 18155

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Dallas

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

  • Details

ClinicalTrials.gov ID: NCT03734016
Diagnosis Type: NA
USOR Number: 18155

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Dallas

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

  • Details

ClinicalTrials.gov ID: NCT04083976
Diagnosis Type: NA
USOR Number: 19092

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Dallas

(MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

  • Details

ClinicalTrials.gov ID: NCT03817853
Diagnosis Type: NA
USOR Number: 18265

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Dallas

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Head and Neck Cancer

Clinical Trial at: Texas Oncology - Dallas

ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

  • Details

ClinicalTrials.gov ID: NCT03689712
Diagnosis Type: NA
USOR Number: 18182

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Cervical Cancer

Clinical Trial at: Texas Oncology - Dallas

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

  • Details

ClinicalTrials.gov ID: NCT03894215
Diagnosis Type: NA
USOR Number: 18223

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number: 19054

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Dallas

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Details

ClinicalTrials.gov ID: NCT03390504
Diagnosis Type: NA
USOR Number: 17133

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Texas Oncology - Dallas

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Dallas

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: NA
USOR Number: 19079

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Dallas

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: NA
USOR Number: 19018

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Pages